PER® Chemotherapy Foundation Symposium (CFS) | Conference

Targeted Therapies Make Major Strides in mCRC Management

November 7th 2021

The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.

Dr. Wirth on the LIBRETTO-531 Trial With Selpercatinib in RET+ Medullary Thyroid Cancer

November 5th 2021

Lori J. Wirth, MD, discusses the phase 3 LIBRETTO-531 trial of selpercatinib in patients with RET-mutant medullary thyroid cancer. 

Dr. Boland on Efforts Underway to Optimize the Utility of ctDNA in CRC

November 5th 2021

Patrick Boland, MD, discusses the utility of circulating tumor DNA in patients with metastatic colorectal cancer.

Dr. Davidson on Leveraging Imaging Technologies to Inform Clinical Decisions in Breast Cancer

November 4th 2021

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Personalized Medicine Could Be the Key to Bridging Health Disparities in Cancer Care

November 4th 2021

Expanding the definition of personalized medicine to include social determinants of health disparities is needed to ensure patients with cancer receive optimal care, said Karen Winkfield, MD, PhD, who added that lessons learned from the COVID-19 pandemic have sparked a new wave of enthusiasm to advocate for change and bridge existing gaps in oncology.

Bispecific Monoclonal Antibodies Lead Immune-Directed Therapies into the Future

November 4th 2021

Increases investigative efforts into bispecific monoclonal antibodies could lead to their availability to treat a broad range of hematologic and solid cancers. Their current use in practice is limited to non–small cell lung cancer, leukemia, and hemophilia.

Checkpoint Blockade Moves Needle in Molecularly Driven Endometrial Cancer Paradigm

November 4th 2021

The management of endometrial cancer, a molecularly driven malignancy with 4 distinct subtypes, has witnessed significant progress with recent regulatory approvals of checkpoint blockade alone and in combination, said Bhavana Pothuri, MD, MS.

Dr. Chari on the Role of MRD Testing in Multiple Myeloma

November 4th 2021

Ajai Chari, MD, discusses recommendations for minimal residual disease testing in patients with multiple myeloma.

COVID-19 Vaccination Remains Imperative for Patients with Cancer

November 4th 2021

As the COVID-19 pandemic persists, patients with cancer should receive the full vaccination with 1 of the 3 approved COVID-19 vaccines as soon as they are able, according to Steven Ludlow, PharmD, BCOP, BCPS.

Dr. Foss on Pursuing New Therapeutic Options in T-Cell Non-Hodgkin Lymphoma

November 3rd 2021

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

Testing for Prognostic Markers Is a Necessity for Optimized CLL Care

November 3rd 2021

The identification of prognostic markers at diagnosis in chronic lymphocytic leukemia is critical, says Deborah M. Stephens, DO, who explains that the results of testing for these markers can be used to educate patients on their prognosis, tailor therapy accordingly, and enroll eligible patients on clinical trials.

MRD Continues to Show Prognostic Potential in AML and Shape Treatment Decisions

November 3rd 2021

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.

Dr. Kremyanskaya on the Need for Disease-Modifying Approaches in MPNs

November 3rd 2021

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

November 8th 2020

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

NCI Director Talks Response to COVID-19 Crisis, Focuses on Overcoming Disruptions in Cancer Care

November 6th 2020

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

Hudis Emphasizes Need for Cancer Research Funding During CFS® Keynote

November 6th 2020

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

Unlocking the Potential of Targeted Treatment Options for HCC

November 6th 2020

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.